School of Medicine, Jiangsu University, Zhenjiang, 212000, China.
Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, 530000, China.
Cell Commun Signal. 2024 May 7;22(1):262. doi: 10.1186/s12964-024-01641-7.
Gene editing of living cells has become a crucial tool in medical research, enabling scientists to address fundamental biological questions and develop novel strategies for disease treatment. This technology has particularly revolutionized adoptive transfer cell therapy products, leading to significant advancements in tumor treatment and offering promising outcomes in managing transplant rejection, autoimmune disorders, and inflammatory diseases. While recent clinical trials have demonstrated the safety of tolerogenic dendritic cell (TolDC) immunotherapy, concerns remain regarding its effectiveness. This review aims to discuss the application of gene editing techniques to enhance the tolerance function of dendritic cells (DCs), with a particular focus on preclinical strategies that are currently being investigated to optimize the tolerogenic phenotype and function of DCs. We explore potential approaches for in vitro generation of TolDCs and provide an overview of emerging strategies for modifying DCs. Additionally, we highlight the primary challenges hindering the clinical adoption of TolDC therapeutics and propose future research directions in this field.
基因编辑活细胞已成为医学研究中的重要工具，使科学家能够解决基本的生物学问题并开发新的疾病治疗策略。这项技术特别改变了过继性转移细胞治疗产品，在肿瘤治疗方面取得了重大进展，并在管理移植排斥、自身免疫性疾病和炎症性疾病方面提供了有希望的结果。尽管最近的临床试验证明了耐受树突状细胞（TolDC）免疫疗法的安全性，但人们仍对其疗效存在担忧。本综述旨在讨论应用基因编辑技术来增强树突状细胞（DC）的耐受功能，特别关注目前正在研究的用于优化 DC 耐受表型和功能的临床前策略。我们探讨了体外生成 TolDC 的潜在方法，并概述了新兴的修饰 DC 的策略。此外，我们强调了阻碍 TolDC 治疗剂临床应用的主要挑战，并提出了该领域未来的研究方向。
